TITLE

ASHP REPORT. Professional policies approved by the 2010 ASHP House of Delegates

PUB. DATE
August 2010
SOURCE
American Journal of Health-System Pharmacy;8/15/2010, Vol. 67 Issue 16, pe50
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses the professional policies approved by the American Society of Health-System Pharmacists (ASHP) House of Delegates in June 2010. It mentions the recommendation for research on the effects of the U.S. Food and Drug Administration's (FAD) Risk Evaluation and Mitigation Strategies (REMS) on the safety of patients and rate of progress of pharmacy. Moreover, the ASHP also recommends that the FDA must eliminate the approval of non-therapeutic utilization of antimicrobials.
ACCESSION #
52952340

 

Related Articles

  • Standardize restricted drug distribution system: ASHP. Vecchione, Anthony // Drug Topics;4/16/2007, Vol. 151 Issue 8, HEALTH-SYSTEM EDITION pHSE17 

    The article explains that the American Society of Health-System Pharmacists (ASHP) has called on the United States Food and Drug Administration (FDA) to standardize restricted drug distribution systems (RDDS) as part of the Prescription Drug User Fee Act (PDUFA) reauthorization. ASHP has...

  • Drug Safety Monitoring. Hampton, Tracy // JAMA: Journal of the American Medical Association;3/23/2005, Vol. 293 Issue 12, p1440 

    Reports that the U.S. Food and Drug Administration has unveiled a new plan to improve drug safety monitoring. Creation of an independent Drug Safety Oversight Board which will focus on making the FDA's review and decision-making processes more independent and transparent; Who will sit on the...

  • Many revisions in drug information compendium.  // Drug Formulary Review;May2007, Vol. 23 Issue 5, p40 

    The article reports on the publication of the 2007 edition of the "AHFS Drug Information" compendium by the American Society of Health-System Pharmacists. The compendium contains 28 new monographs and thousands of revisions, which include updates of major cautionary information from the U.S....

  • News Briefs.  // American Journal of Health-System Pharmacy;11/15/2007, Vol. 64 Issue 22, p2319 

    The article offers news briefs related to the pharmaceutical industry in the U.S. The Food and Drugs Administration announced changes to the iPledge restricted-distribution program for isotretinoin products. In addition, the American Society of Health-System Pharmacists (ASHP) became a member of...

  • ASHP to develop standardized concentrations of IV and oral drugs. Blank, Christine // Drug Topics;Oct2015, Vol. 159 Issue 10, p35 

    The article reports that the American Society of Health-System Pharmacists (ASHP) has entered a contract with the U.S. Food & Drug Administration (FDA) in 2015 to develop standardized concentrations for intravenous (IV) and oral liquid medications in the U.S.

  • Antimicrobial stewardship: are we failing in cross-specialty clinical engagement? Rawson, Timothy M.; Moore, Luke S. P.; Gilchrist, Mark J.; Holmes, Alison H. // Journal of Antimicrobial Chemotherapy (JAC);Feb2016, Vol. 71 Issue 2, p554 

    Background: Antimicrobial resistance (AMR) is a public health priority and leading patient safety issue. Globally, antimicrobial stewardship (AMS) has been integral in promoting therapeutic optimization whilst minimizing harmful antimicrobial use. A cross-sectional, observational study was...

  • Labeling changes announced for Ketek.  // Drug Topics;2/19/2007, Vol. 151 Issue 4, p9 

    The article reports on the changes made by the U.S. Food and Drug Administration (FDA) to the labeling of the antibiotic telithromycin Ketek developed by Sanofi-Aventis SA. FDA has approved Ketek for treating community-acquired pneumonia (CAP) of mild to moderate severity and not to be indicated...

  • Hospitals are encouraged to remove propoxyphene.  // Drug Formulary Review;Jun2008, Vol. 24 Issue 6, p45 

    The article reports that the American Society of Health-System Pharmacists (ASHP) of Bethesda, Maryland has urged the U.S. Food and Drug Administration to remove synthetic opioid propoxyphene from the market. Synthetic opioid propoxyphene is marketed as Darvon® or propoxyphene plus...

  • FDA reopens comment period on proposed changes to generic labeling. Foxhall, Kathryn // Drug Topics;May2015, Vol. 159 Issue 5, p24 

    The article reports on the reopening of the comment period on proposed changes to generic labeling by the U.S. Food and Drug Administration (FDA). Topics discussed include the need for generic drug manufacturers to notify the FDA if they want to add the newly acquired safety information to...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics